NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

|  |  |
| --- | --- |
| **1.** | **Notifying Member:** BRAZIL**If applicable, name of local government involved (Article 3.2 and 7.2):**  |
| **2.** | **Agency responsible:** Brazilian Health Regulatory Agency (ANVISA)**Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:** National Institute of Metrology, Quality and Technology (INMETRO)Telephone: +(55) 21 2145.3817Telefax: +(55) 21 2563.5637Email: barreirastecnicas@inmetro.gov.brWebsite: www.inmetro.gov.br/barreirastecnicas |
| **3.** | **Notified under Article 2.9.2 [****X],** **2.10.1 [****],** **5.6.2 [****],** **5.7.1 [****], 3.2 [****], 7.2 [****],** **other****:**  |
| **4.** | **Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):** Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale. (HS code(s): 3003); Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. (HS code(s): 3004) |
| **5.** | **Title, number of pages and language(s) of the notified document:** Resolution - RDC number 730, 01 July 2022; (10 page(s), in Portuguese) |
| **6.** | **Description of content:** This Resolution contains provisions on human health risk assessment of veterinary medicinal products, maximum residue limits (MRLs) of veterinary medicinal products in foods of animal origin and methods of analysis for conformity assessment purposes. Studies should be conducted and reported in accordance with updated protocols described in the Organization for Cooperation and Economic Development (OECD) or guidelines published in theInternational Conference on Harmonization of Veterinary Medicines (VICH) and follow the principles of Good Laboratory Practice (GLP).This resolution will also be notified to the SPS committee |
| **7.** | **Objective and rationale, including the nature of urgent problems where applicable:** Protection of human health or safety |
| **8.** | **Relevant documents:** - |
| **9.** | **Proposed date of adoption:** 1 September 2022**Proposed date of entry into force:** 1 September 2022 |
| **10.** | **Final date for comments:** Not Applicable |
| **11.** | **Texts available from: National enquiry point [****]** **or address, telephone and fax numbers and email and website addresses, if available, of other body:** Brazilian Health Regulatory Agency (Anvisa)SIA, Trecho 5, Área Especial 57Brasília – DF / BrazilCEP: 71.205-050Phone.: +(55) 61 3462.5402Website: www.anvisa.gov.brThe final text is available only in Portuguese and can be downloaded at:<http://antigo.anvisa.gov.br/documents/10181/2718376/RDC_730_2022_.pdf/0dfa65ac-4176-414b-a130-564dac564e44> |